| Paroxysmal nocturnal hemoglobinuria
Voydeya vs Empaveli
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Voydeya vs Empaveli with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEmpaveli has a higher rate of injection site reactions vs Voydeya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Empaveli but not Voydeya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Voydeya
Empaveli
At A Glance
Oral
Three times daily
Complement Factor D inhibitor
SC injection
Twice weekly
C3 complement inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Paroxysmal nocturnal hemoglobinuria
- C3 glomerulopathy
- Immune-complex membranoproliferative glomerulonephritis
Dosing
Paroxysmal nocturnal hemoglobinuria 150 mg orally three times a day as starting dose; may increase to 200 mg three times a day if hemoglobin has not increased by >2 g/dL after 4 weeks, if transfusion was required in the previous 4 weeks, or based on clinical judgment.
Paroxysmal nocturnal hemoglobinuria 1,080 mg SC twice weekly; adjust to 1,080 mg every three days if LDH >2x ULN.
C3 glomerulopathy, Immune-complex membranoproliferative glomerulonephritis Adults: 1,080 mg SC twice weekly; pediatric patients (12 to <18 years): weight-based dosing from 648 mg to 1,080 mg SC twice weekly based on body weight.
Contraindications
- Unresolved serious infection caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B
- Hypersensitivity to pegcetacoplan or any excipient
- Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B
Adverse Reactions
Most common (>=10%) Headache
Serious Pancreatitis, cholecystitis, blood bilirubin increased
Most common (>=10%) Injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, fatigue
Serious Infections, intestinal ischemia, biliary sepsis, hypersensitivity pneumonitis
Postmarketing Anaphylaxis, urticaria
Pharmacology
Complement Factor D inhibitor; danicopan binds reversibly to Factor D and selectively inhibits the alternative complement pathway, preventing C3 convertase formation, reducing C3 fragment opsonization, and thereby controlling extravascular hemolysis in PNH when used as add-on therapy to a terminal complement inhibitor.
C3 complement inhibitor; pegcetacoplan binds complement protein C3 and its activation fragment C3b, regulating downstream complement activation to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit C3 glomerular fragment deposition and C5b-9 assembly in C3G and primary IC-MPGN.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Voydeya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Empaveli
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Voydeya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Empaveli
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Voydeya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Empaveli
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Alexion OneSourceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableApellis Bridge Program: Empaveli
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VoydeyaView full Voydeya profile
EmpaveliView full Empaveli profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.